NCT07132645 2025-09-23
An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Recruiting
Clinical Trials
16 trialsNCT03335670 2025-07-14
Gallium 68 Pentixafor in Patients With Neuroendocrine Tumors
University of Iowa
Phase EARLY_PHASE1 Active not recruiting
NCT04544098 2025-05-02
Lutathera in People With Gastroenteropancreatic (GEP), Bronchial or Unknown Primary Neuroendocrine Tumors That Have Spread to the Liver
Memorial Sloan Kettering Cancer Center
Phase EARLY_PHASE1 Active not recruiting
NCT04510311 2025-01-10
Imaging Properties of PET Radiotracer [18F]3F-PHPG in Patients With Neuroendocrine Tumors
University of Michigan Rogel Cancer Center
Phase EARLY_PHASE1 Completed
NCT01873248 2024-07-19
Impact of 68Ga-DOTATATE PET/CT on the Management of Neuroendocrine Tumors: The Referring Physician's Perspective
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Completed
NCT05359146 2024-04-19
Beta plus
University Hospital, Basel, Switzerland
Phase EARLY_PHASE1 Recruiting
NCT05069220 2024-03-01
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Recruiting
NCT03724409 2023-11-28
Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases
University of Iowa
Phase EARLY_PHASE1 Terminated
NCT05871320 2023-09-29
TECANT
Jagiellonian University
Phase EARLY_PHASE1 Completed
NCT04897542 2023-09-18
Gallium-68 NODAGA-JR11 PECT/CT in Neuroendocrine Tumors
First Affiliated Hospital of Fujian Medical University
Phase EARLY_PHASE1 Unknown
NCT03623984 2023-09-11
Molecular-Guided Surgery for Pancreatic and GI Neuroendocrine Cancers
University of Alabama at Birmingham
Phase EARLY_PHASE1 Withdrawn
NCT03044977 2023-08-16
Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors
University of Iowa
Phase EARLY_PHASE1 Active not recruiting
NCT02817945 2022-04-07
Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown
NCT03001349 2021-02-15
68Ga-DOTA-TOC PET/CT in Imaging Participants With Neuroendocrine Tumors
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03197012 2020-07-07
Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor
University of California, San Francisco
Phase EARLY_PHASE1 Completed
NCT04041882 2019-08-01
68Ga-DOTATATE PET/CT in Neuroendocrine Tumor
Peking Union Medical College Hospital
Phase EARLY_PHASE1 Unknown